Cathrine J. DeMars
Mayo Clinic
17 Papers
121 Citations
Cathrine J. DeMars is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Barrett's esophagus & Esophagus. The author has an hindex of 6, co-authored 17 publications. Previous affiliations of Cathrine J. DeMars include University of Rochester.
Chat about Author
Papers
Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells.
Francesca Milano,Jantine W. van Baal,Navtej S. Buttar,Agnieszka M. Rygiel,Floor de Kort,Cathrine J. DeMars,Wilda D. Rosmolen,Jacques J. Bergman,Jan van Marle,Kenneth K. Wang,Maikel P. Peppelenbosch,Kausilia K. Krishnadath +11 more
TL;DR: It is suggested that the BMP pathway could play a role in the transformation of normal esophageal squamous cells into columnar cells.
174
Sequence-specific recruitment of heterochromatin protein 1 via interaction with Krüppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases.
Gwen Lomberk,Angela Mathison,Adrienne Grzenda,Seungmae Seo,Cathrine J. DeMars,Sumera Rizvi,Juliana Bonilla-Velez,Ezequiel Calvo,Martin E. Fernandez-Zapico,Juan L. Iovanna,Navtej S. Buttar,Raul Urrutia +11 more
TL;DR: A novel role for HP1 is revealed as a cofactor in tumor suppression, the mechanistic understanding of a KLF associated to human disease is expanded, and cellular and biochemical mechanisms underlying this phenomenon are outlined, increasing the specificity of targeting HP1-HMT complexes to gene promoters.
50
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
Sumera Rizvi,Cathrine J. DeMars,Andrea Comba,Vladimir G. Gainullin,Zaheer H. Rizvi,Luciana L. Almada,Kenneth K. Wang,Gwen Lomberk,Martin E. Fernandez-Zapico,Navtej S. Buttar +9 more
TL;DR: Results identify a novel GLI1-to-CDK2 pathway in esophageal carcinogenesis, which is a bona fide target for effective combinatorial chemoprevention with Urso and Aspirin.
47
Chemoprevention in Barrett's esophagus.
TL;DR: Various potential chemoprevention targets and rationale behind their use to prevent Barrett’s related esophageal adenocarcinoma are discussed and critically appraise the emerging preclinical and clinical literature regarding prevention of neoplasia in Barrett's esophagus.
8